{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:42:15Z","timestamp":1787002935954,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-025-01049-5","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:56:59Z","timestamp":1761541019000},"page":"449-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Testosterone suppression and recovery with abiraterone\/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"given":"Autumn","family":"Gagnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiwei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Morlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dory","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Trowbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Kilbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-0289","authenticated-orcid":false,"given":"Bradley A.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-6631","authenticated-orcid":false,"given":"Atish D.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447\u201360.","journal-title":"Lancet"},{"key":"1049_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/JCO.2023.41.6_suppl.178","volume":"41","author":"P Ravi","year":"2023","unstructured":"Ravi P, Huang J, Xie W, Whelpley B, Kelly E, McGregor BA, et al. Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC). J Clin Oncol. 2023;41:178.","journal-title":"J Clin Oncol"},{"key":"1049_CR3","doi-asserted-by":"crossref","unstructured":"Morgans AK, Niazi T, Shore ND, Gschwend JE, Ross A, Hope TA, et al. Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: a phase 3, randomized, double-blind, placebo-controlled study (ARASTEP). J Clin Oncol 2024;42.","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS254"},{"key":"1049_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","volume":"87","author":"WL Ong","year":"2025","unstructured":"Ong WL, Romero T, Roy S, Nikitas J, Joseph D, Zapatero A, et al. Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): a pooled analysis of five randomized trials from the meta-analysis of randomized trials in cancer of the prostate (MARCAP) consortium. Eur Urol. 2025;87:49\u201357.","journal-title":"Eur Urol"},{"key":"1049_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110256","volume":"195","author":"A Nabid","year":"2024","unstructured":"Nabid A, Carrier N, Vigneault E, Martin AG, Bahary JP, Van Nguyen T, et al. Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials. Radiother Oncol. 2024;195:110256.","journal-title":"Radiother Oncol"},{"key":"1049_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.euros.2023.12.003","volume":"60","author":"MA Preston","year":"2024","unstructured":"Preston MA, Hong A, Dufour R, Marden JR, Kirson NY, Gatoulis SC, et al. Implications of delayed testosterone recovery in patients with prostate cancer. Eur Urol Open Sci. 2024;60:32\u20135.","journal-title":"Eur Urol Open Sci"},{"key":"1049_CR7","doi-asserted-by":"crossref","unstructured":"Nabid A, Carrier N, Martin A-G, Bahary J-P, Vavassis P, Vass S, et al. Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: long-term data from a phase III trial. J Clin Oncol. 2025;43:310\u2013310.","DOI":"10.1200\/JCO.2025.43.5_suppl.310"},{"key":"1049_CR8","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. Hormonal impact of the 17\u03b1-hydroxylase\/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317\u201325.","journal-title":"Br J Cancer"},{"key":"1049_CR9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41391-022-00533-6","volume":"25","author":"C-H Ohlmann","year":"2022","unstructured":"Ohlmann C-H, J\u00e4schke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. LHRH sparing therapy in patients with chemotherapy-na\u00efve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer Prostatic Dis. 2022;25:778\u201384.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1049_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/pros.24589","volume":"83","author":"AT Arafa","year":"2023","unstructured":"Arafa AT, Blader LR, Ramakrishna K, Engle J, Ryan CJ, Zorko NA, et al. Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: a retrospective case-control study. Prostate. 2023;83:1279\u201384.","journal-title":"Prostate"},{"key":"1049_CR11","doi-asserted-by":"crossref","unstructured":"Makrakis D, Goel S, O\u2019Sullivan D, White M, Gartrell BA. Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): a single arm, phase II study. J Clin Oncol. 2024;42:5086\u20135086.","DOI":"10.1200\/JCO.2024.42.16_suppl.5086"},{"key":"1049_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.euros.2021.09.015","volume":"34","author":"KA Autio","year":"2021","unstructured":"Autio KA, Antonarakis ES, Mayer TM, Shevrin DH, Stein MN, Vaishampayan UN, et al. Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy. Eur Urol Open Sci. 2021;34:70\u20138.","journal-title":"Eur Urol Open Sci"}],"updated-by":[{"DOI":"10.1038\/s41391-025-01055-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01049-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:42:17Z","timestamp":1779331337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01049-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01049-5","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In Table 1, each value in \u201cTime to T recovery after treatment discontinuation\u201d need to be shifted to the right.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-025-01055-7","URL":"https:\/\/doi.org\/10.1038\/s41391-025-01055-7","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC: Honoraria for Speaking Arrangement: Pfizer, Lantheus, Bayer. Consulting: Tolmar, Janssen, Johnson & Johnson, Sanofi Aventis, Pfizer, Astellas, Bayer, Daiichi Sankyo, Boundless Bio, Novartis. Research Funding to Institution: Merck, Bayer, Eli Lilly, Pfizer, Sumitomo Pharma America. WX: Consulting: Prostate Cancer Clinical Trials Consortium. KK: Research Funding to Institution: Pfizer ACS. BM: Consulting: Arcus, Aveo, BMS, Daiichi, Exelixis, Eisai, Gilead, Genmab, Hexagon, Lily, Pfizer. Research Funding to Institution: Aveo, BMS, Exelixis, Gilead, Merck, Pfizer. MT: Honoraria for Speaking Arrangement: AstraZeneca. Consulting: AstraZeneca, Blue Earth, Pfizer, Janssen, Johnson & Johnson, Astellas, Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}